MedTrace Logo

A Clinical Trial on the Antipsychotic Properties of Cannabidiol

NCT00309413 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2008-07-25

No results posted yet for this study

Summary

The purpose of this study is to determine whether cannabidiol, a herbal cannabinoid, is effective in the treatment of acute schizophrenic or schizophreniform psychosis in a placebo-controlled, randomized double-blind study.

Conditions

Interventions

DRUG

Placebo/Cannabidiol

600 mg/day, oral, capsules, 2 weeks, than cross-over

DRUG

Cannabidiol/Placebo

600 mg/day, oral, capsules, 2 weeks, than cross-over

Sponsors & Collaborators

  • Stanley Medical Research Institute

    collaborator OTHER

  • Coordinating Centre for Clinical Trials Cologne

    collaborator OTHER

  • University of Cologne

    lead OTHER

Principal Investigators

  • F. Markus Leweke, MD · University of Cologne

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-03-31
Primary Completion
2008-03-31
Completion
2008-07-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00309413 on ClinicalTrials.gov